SEC INSIDER TRANSACTIONS

METLIFE INC (MET-PE) Insider Transactions

Explore official ownership filings, with every record linked to its source.

Reported data · not live

MET-PE · METLIFE INC

Filing window SEC codes (comma separated) Security type Order

More transaction filters

Roles: director,officer,ten_percent_owner,otherOwner nameOfficer titleOwnership: D, I, unknownoriginal or amendedTransaction fromTransaction throughFiled fromFiled throughMinimum quantityMaximum quantityMinimum priceMaximum priceMinimum calculated valueMaximum calculated valueResults per page (1–100)

OR within codes/roles; AND between categories. Roles apply to buyers and sellers. Owner predicates match the same owner. Missing values fail numeric/date filters. Value is quantity × reported price for non-derivative rows only; derivative values are unknown. Amendments stay separate; joint owners do not duplicate rows.

Reset filters

Active filters: days=6m

Stale snapshot · Covered: filings 2026-05-14 to 2026-11-13 · 44 filings · fetched 2026-11-13T18:57:13Z

Recent reported activity

0purchase rows on this page

1sale rows on this page

56matching filing rows

Purchases and sales count original non-derivative P and S rows. Awards, gifts, exercises, derivatives and amendments are shown separately and are not described as market purchases.

Transaction / filed	Reporting owner(s)	Code / security	Quantity	Price as filed	Ownership	Source
2026-06-09Filed 2026-06-11	Kennard William EDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred. F2 Shares held in trust under the MetLife Policyholder Trust established to hold shares of common stock allocated to eligible policyholders of Metropolitan Life Insurance Company, a wholly-owned subsidiary of MetLife, Inc. References: F1	A Award / grantCommon Stock · Non-derivative	322A	85.57	Direct	Form 4 ↗0001198236-26-000009
2026-06-01Filed 2026-06-03	DEBEL MARLENEOfficer · EVP & Chief Risk Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price reported is the weighted average price of the aggregate number of shares sold in multiple open market transactions. The shares were sold at prices between $81.57 to $81.65, inclusive. The reporting person undertakes to provide to the staff of the SEC, MetLife, Inc., or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price. F2 The options became exercisable in three substantially equal installments on February 28, 2018, 2019, and 2020. F3 The options became exercisable in three substantially equal installments on March 2, 2019, 2020, and 2021. References: F3	M Exercise / conversionEmployee Stock Options (right to buy) · Derivative	10,712D	0	Direct	Form 4 ↗0001770295-26-000007
2026-06-01Filed 2026-06-03	DEBEL MARLENEOfficer · EVP & Chief Risk Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price reported is the weighted average price of the aggregate number of shares sold in multiple open market transactions. The shares were sold at prices between $81.57 to $81.65, inclusive. The reporting person undertakes to provide to the staff of the SEC, MetLife, Inc., or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price. F2 The options became exercisable in three substantially equal installments on February 28, 2018, 2019, and 2020. F3 The options became exercisable in three substantially equal installments on March 2, 2019, 2020, and 2021. References: F2	M Exercise / conversionEmployee Stock Options (right to buy) · Derivative	10,600D	0	Direct	Form 4 ↗0001770295-26-000007
2026-06-01Filed 2026-06-03	DEBEL MARLENEOfficer · EVP & Chief Risk Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price reported is the weighted average price of the aggregate number of shares sold in multiple open market transactions. The shares were sold at prices between $81.57 to $81.65, inclusive. The reporting person undertakes to provide to the staff of the SEC, MetLife, Inc., or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price. F2 The options became exercisable in three substantially equal installments on February 28, 2018, 2019, and 2020. F3 The options became exercisable in three substantially equal installments on March 2, 2019, 2020, and 2021. References: F1	S Sale (market/private)Common Stock · Non-derivative	21,312D	81.5889	Direct	Form 4 ↗0001770295-26-000007
2026-06-01Filed 2026-06-03	DEBEL MARLENEOfficer · EVP & Chief Risk Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price reported is the weighted average price of the aggregate number of shares sold in multiple open market transactions. The shares were sold at prices between $81.57 to $81.65, inclusive. The reporting person undertakes to provide to the staff of the SEC, MetLife, Inc., or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price. F2 The options became exercisable in three substantially equal installments on February 28, 2018, 2019, and 2020. F3 The options became exercisable in three substantially equal installments on March 2, 2019, 2020, and 2021. References:	M Exercise / conversionCommon Stock · Non-derivative	10,712A	45.5	Direct	Form 4 ↗0001770295-26-000007
2026-06-01Filed 2026-06-03	DEBEL MARLENEOfficer · EVP & Chief Risk Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price reported is the weighted average price of the aggregate number of shares sold in multiple open market transactions. The shares were sold at prices between $81.57 to $81.65, inclusive. The reporting person undertakes to provide to the staff of the SEC, MetLife, Inc., or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price. F2 The options became exercisable in three substantially equal installments on February 28, 2018, 2019, and 2020. F3 The options became exercisable in three substantially equal installments on March 2, 2019, 2020, and 2021. References:	M Exercise / conversionCommon Stock · Non-derivative	10,600A	46.85	Direct	Form 4 ↗0001770295-26-000007

Imported instruments only. Joint owners do not multiply transactions. Amendments are separate filing rows, not additional trades. No aggregate trade totals are implied.